Shen Liangfang, Huang Xinqiong, Xie Xiaoxue, Su Juan, Yuan Jun, Chen Xiang
Department of Oncology (LS, XH, JY), Xiangya Hospital, Central South University, Hunan Province, P.R. ChinaDepartment of Dermatology (XC, JS), Xiangya Hospital, Central South University, Hunan Province, P.R. ChinaDepartment of Radiation Oncology (XX), Hunan Provincial Tumal Hospital & Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Hunan Province, P.R. China.
Department of Oncology (LS, XH, JY), Xiangya Hospital, Central South University, Hunan Province, P.R. ChinaDepartment of Dermatology (XC, JS), Xiangya Hospital, Central South University, Hunan Province, P.R. ChinaDepartment of Radiation Oncology (XX), Hunan Provincial Tumal Hospital & Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Hunan Province, P.R. China
J Histochem Cytochem. 2014 Jul;62(7):499-509. doi: 10.1369/0022155414532654. Epub 2014 Apr 7.
Radiotherapy (RT) as a preoperative or postoperative adjuvant or primary treatment is the most common management modality for locally advanced cervical cancer. Radioresistance of tumor cells remains a major therapeutic problem. Consequently, we aimed to explore if the stem cell biomarkers SOX2 and OCT4 protein could be used to predict radioresistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC). These 132 patients were divided into two groups (radiation-resistant and radiation-sensitive groups) according to progress-free survival (PFS). Using pretreatment paraffin-embedded tissues, we evaluated SOX2 and OCT4 expression using immunohistochemical staining. The percentage of overexpression of SOX2 and OCT4 in the radiation-resistant group was much higher than that in the radiation-sensitive group (p<0.001 and p <0.001, respectively). The patients with high expression of SOX2 and OCT4 showed a shorter PFS than those with low expression. Our study suggests that the expression of SOX2 and OCT4 in tumor cells indicates resistance to radiotherapy and that these two factors were important predictors of poor survival in patients with LACSCC (hazard ratio [95% CI], 2.294 [1.013, 5.195] and 2.300 [1.050, 5.037], respectively; p=0.046 and p=0.037, respectively).
放射治疗(RT)作为术前或术后辅助治疗或主要治疗手段,是局部晚期宫颈癌最常见的治疗方式。肿瘤细胞的放射抗性仍然是一个主要的治疗难题。因此,我们旨在探讨干细胞生物标志物SOX2和OCT4蛋白是否可用于预测局部晚期宫颈鳞状细胞癌(LACSCC)患者的放射抗性。根据无进展生存期(PFS)将这132例患者分为两组(放射抗性组和放射敏感组)。我们使用预处理的石蜡包埋组织,通过免疫组织化学染色评估SOX2和OCT4的表达。放射抗性组中SOX2和OCT4的过表达百分比远高于放射敏感组(分别为p<0.001和p<0.001)。SOX2和OCT4高表达的患者的无进展生存期比低表达患者短。我们的研究表明,肿瘤细胞中SOX2和OCT4的表达表明对放射治疗有抗性,并且这两个因素是LACSCC患者生存不良的重要预测指标(风险比[95%CI],分别为2.294[1.013,5.195]和2.300[1.050,5.037];p分别为0.046和0.037)。